Activity of the leukotriene pathway in Barrett's metaplasia and oesophageal adenocarcinoma

Inflammation Research

Volumn 61, Issue 12, 2012, Pages 1379-1384

  Shutt, James David ^a,b   Boger, Philip ^a,b   Neale, James Richard ^a,b   Patel, Praful ^a   Sampson, Anthony Peter ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

5 LOX; Cancer; GI disease; Leukotrienes

Indexed keywords

CALCIMYCIN; LEUKOTRIENE; LEUKOTRIENE B4; PEPTIDOLEUKOTRIENE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DYSPLASIA; ENZYME IMMUNOASSAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOGENESIS; MALE; MITOGENESIS; TISSUE CULTURE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; LEUKOTRIENES; MALE; METAPLASIA; MIDDLE AGED;

EID: 84872203035     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0539-2     Document Type: Article

References (42)

1. Jankowski J, Barr H, Wang K, Delaney B. Diagnosis and management of Barrett's oesophagus. BMJ. 2010;341:c4551. doi: 10.1136/bmj.c4551 .
2. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology. 2002;122:588-90 .
3. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999: results and commentary. Eur J Cancer. 2009;45:931-91 .
4. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009;10:351-69 .
5. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis. 2001;22:1119-29 .
6. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181-93 .
7. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-5 .
8. Mehta S, Boddy A, Johnson IT, Rhodes M. Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther. 2006;24:1321-31 .
9. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the aspect trial. Recent Results Cancer Res. 2009;181:161-9 .
10. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med. 2007;357:1841-54 .
11. Massoumi R, Sjölander A. The role of leukotriene receptor signaling in inflammation and cancer. Scientific World J. 2007;7: 1413-21 .
12. Chen X, Li N, Wang S, Wu N, Hong J, Jiao X, et al. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Nat Cancer Inst. 2003;95:1053-61 .
13. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res. 2004;10:6703-9 .
14. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005;26:785-91 .
15. Chen X, Li N, Wang S, Hong J, Fang M, Yousselfson J, et al. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis. 2002;23:2095-102 .
16. Triadafilopoulos G, Kaczynska M, Iwane M. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus. Am J Gastroenterol. 1996;91:65-74 .
17. Boger PC, Shutt JD, Neale JR, Wilson SW, Bateman AC, Holloway JW, Patel P, SampsonAP. Increased expression of the 5-lipoxygenase pathway and its cellular localisation in Barrett's adenocarcinoma. Histopathology. 2012. doi:10.1111/j.1365-2559.2012.04258.x
18. Ahmed A, Salmon PR, Cairns CR, Hobsley M, Hoult Jr. Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate. Gut. 1992;33:159-63 .
19. Hawthorne AB, Boughton-Smith NK, Whittle BJ, Hawkey CJ. Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. Gut. 1992;33:513-7 .
20. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukot Essent Fat Acids. 2003;69:123-34 .
21. Islam SA, Thomas SY, Hess C, Medoff BD, Means TK, Brander C, et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood. 2006;107: 444-53 .
22. Shin EH, Lee HY, Bae YS. Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis. Biochem Biophys Res Commun. 2006;348:606-11 .
23. Kim GY, Lee JW, Cho SH, Seo JM, Kim JH. Role of the lowaffinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29:915-20 .
24. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun. 2005;335:949-56 .
25. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci. 2007;103:24-32 .
26. Jeong CH, Bode AM, Pugliese A, Cho YY, Kim HG, Shim JH, et al. [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res. 2009;69:5584-91 .
27. Hennig R, Ventura J, Segersvard R, Ward E, Ding XZ, Rao SM, et al. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia. 2005;7:417-25 .
28. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-93 .
29. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531-6 .
30. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/ cysteinyl-leukotrienes receptor. EMBO J. 2006;25:4615-27 .
31. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med. 2009;206:2543-55 .
32. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem. 2001;276:22608-13 .
33. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction. Eur J Pharmacol. 1994;258:151-4 .
34. Mezhybovska M, Wikstrom K, Ohd JF, Sjolander A. The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J Biol Chem. 2006;281:6776-84 .
35. Paruchuri S, Mezhybovska M, Juhas M, Sjolander A. Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells. Oncogene. 2006;25:6660-5 .
36. Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, Takemoto Y, et al. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol Rep. 2007;18:99-104 .
37. Magnusson C, Ehrnstrom R, Olsen J, Sjolander A. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res. 2007;67:9190-8 .
38. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology. 2003;124:57-70 .
39. Hsieh FH, Sharma P, Gibbons A, Goggans T, Erzurum SC, Haque SJ. Human airway epithelial cell determinants of survival and functional phenotype for primary human mast cells. Proc Natl Acad Sci USA. 2005;102:14380-5 .
40. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50:451-9 .
41. Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, Schiavone N, et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther. 2006;5:2716-26 .
42. Schroeder CP, Yang P, Newman EA, Lotan R. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol. 2007;6:183-92 .